{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:48:00Z","timestamp":1789274880430,"version":"build-2803163510"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":104,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Lundbeck Foundation Professor Grant","award":["R310-2018-3711"],"award-info":[{"award-number":["R310-2018-3711"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Erenumab has proven effective for migraine prevention; however, a substantial proportion of people with migraine do not benefit from treatment, and among those who do, there is considerable variability in response. This study aimed to identify clinical predictors of therapeutic response to erenumab and evaluate their predictive value in a large cohort of people with migraine. We conducted a single-centre, prospective, longitudinal cohort study of adults with migraine, experiencing \u22654 monthly migraine days. All participants received erenumab 140\u2005mg monthly for 24 weeks and recorded their response in a headache diary with daily entries. A semi-structured interview was conducted at enrolment, and patient-reported outcome measures were collected before and after treatment. Treatment responders were classified as participants achieving a reduction from baseline of \u226550% in average monthly migraine days across weeks 13 through 24. Clinical predictors were analysed using logistic regression analysis. In total, 570 participants with migraine provided data eligible for analysis. Of these, 298 (52.3%) participants were classified as treatment responders, and the remaining 272 (47.7%) were non-responders. Independent predictors associated with a lower likelihood of response to erenumab were chronic migraine (odds ratio 0.63, 95% confidence interval 0.43\u20130.91; P = 0.030), daily headache (odds ratio 0.41, 95% confidence interval 0.24\u20130.67; P = 0.003) and previous failure of \u22653 preventive migraine medications (odds ratio 0.54, 95% confidence interval 0.37\u20130.77; P = 0.005). Conversely, better outcomes were observed with higher age (10-year increase: odds ratio 1.22, 95% confidence interval 1.06\u20131.41; P = 0.017). Multivariate model area under curve was 64.6% (60.0\u201369.2%). Participants with an early response to erenumab (\u226550% reduction within weeks 1\u201312) were less likely than late responders to have chronic migraine [119\/217 (57.1%) versus 61\/79 (77.2%); P &amp;lt; 0.001], had lower Migraine Disability Assessment Scores [median (IQR): 52 (30\u201385) versus 65 (35\u2013120); P = 0.029], more often had unilateral headache [193 (88.9%) versus 63\/79 (79.7%); P = 0.041], and experienced less ictal allodynia measured by Allodynia Symptom Checklist-12 scores [median (IQR): 4 (0\u20138) versus 6 (2\u20138) versus; P = 0.024]. In conclusion, chronic migraine, experiencing daily headache, and having \u22653 preventive medication failures were independently associated with a lower likelihood of response to erenumab. Moreover, patients with a more severe clinical phenotype were more likely to respond later. Prediction of treatment responses might be improved by incorporating machine learning models and multimodal biomarkers, facilitating a shift towards personalized medicine.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaf147","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T08:36:51Z","timestamp":1744706211000},"source":"Crossref","is-referenced-by-count":4,"title":["Clinical predictors for efficacy of erenumab for migraine: a Registry for Migraine (REFORM) study"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0339-1417","authenticated-orcid":false,"given":"William Kristian","family":"Karlsson","sequence":"first","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital\u2014Rigshospitalet , Copenhagen 2600 ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen 2100 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital\u2014Rigshospitalet , Copenhagen 2600 ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen 2100 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune H\u00e4ckert","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital\u2014Rigshospitalet , Copenhagen 2600 ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen 2100 ,","place":["Denmark"]},{"name":"Translational Research Center, Copenhagen University Hospital\u2014Rigshospitalet , Copenhagen 2600 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidar Muhsen","family":"Al-Khazali","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital\u2014Rigshospitalet , Copenhagen 2600 ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen 2100 ,","place":["Denmark"]},{"name":"Translational Research Center, Copenhagen University Hospital\u2014Rigshospitalet , Copenhagen 2600 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-727X","authenticated-orcid":false,"given":"H\u00e5kan","family":"Ashina","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital\u2014Rigshospitalet , Copenhagen 2600 ,","place":["Denmark"]},{"name":"Translational Research Center, Copenhagen University Hospital\u2014Rigshospitalet , Copenhagen 2600 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"19","key":"2025042302470848400_fcaf147-B1","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"Ashina","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2025042302470848400_fcaf147-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-021-00328-4","article-title":"Migraine","volume":"8","author":"Ferrari","year":"2022","journal-title":"Nat Rev Dis Primers."},{"issue":"3","key":"2025042302470848400_fcaf147-B3","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","article-title":"The arrival of anti-CGRP monoclonal antibodies in migraine","volume":"19","author":"Cohen","year":"2022","journal-title":"Neurotherapeutics"},{"key":"2025042302470848400_fcaf147-B4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","article-title":"Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: A 52-week, single-center, prospective, observational study","volume":"23","author":"Cullum","year":"2022","journal-title":"J Headache Pain."},{"issue":"1","key":"2025042302470848400_fcaf147-B5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-022-01408-w","article-title":"Comparing the relative and absolute effect of erenumab: Is a 50% response enough? Results from the ESTEEMen study","volume":"23","author":"Ornello","year":"2022","journal-title":"J Headache Pain"},{"key":"2025042302470848400_fcaf147-B6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/TCRM.S263825","article-title":"Migraine prevention with erenumab: Focus on patient selection, perspectives and outcomes","volume":"18","author":"De Matteis","year":"2022","journal-title":"Ther Clin Risk Manag."},{"issue":"10","key":"2025042302470848400_fcaf147-B7","first-page":"927","article-title":"Redefining migraine prevention: Early treatment with anti-CGRP monoclonal antibodies enhances response in the real world","volume":"95","author":"Caronna","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2025042302470848400_fcaf147-B8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","article-title":"Predictors of response to anti-CGRP monoclonal antibodies: A 24-week, multicenter, prospective study on 864 migraine patients","volume":"23","author":"Barbanti","year":"2022","journal-title":"J Headache Pain"},{"issue":"1","key":"2025042302470848400_fcaf147-B9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s10194-023-01552-x","article-title":"Clinical evaluation of super-responders vs. Non-responders to CGRP(-receptor) monoclonal antibodies: A real-world experience","volume":"24","author":"Raffaelli","year":"2023","journal-title":"J Headache Pain"},{"issue":"4","key":"2025042302470848400_fcaf147-B10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/ene.15197","article-title":"Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study","volume":"29","author":"Vernieri","year":"2022","journal-title":"Eur J Neurol"},{"issue":"4","key":"2025042302470848400_fcaf147-B11","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/ene.15236","article-title":"Clinic and genetic predictors in response to erenumab","volume":"29","author":"Zecca","year":"2022","journal-title":"Eur J Neurol."},{"issue":"1","key":"2025042302470848400_fcaf147-B12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","article-title":"Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: A single-centre retrospective observational study","volume":"24","author":"Ihara","year":"2023","journal-title":"J Headache Pain"},{"issue":"1","key":"2025042302470848400_fcaf147-B13","doi-asserted-by":"crossref","first-page":"14825","DOI":"10.1038\/s41598-023-42110-4","article-title":"Predictors of galcanezumab response in a real-world study of Korean patients with migraine","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"2025042302470848400_fcaf147-B14","doi-asserted-by":"crossref","first-page":"e000547","DOI":"10.1136\/bmjno-2023-000547","article-title":"Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: Results of an Australian multicentre study","volume":"6","author":"Ray","year":"2024","journal-title":"BMJ Neurol Open"},{"key":"2025042302470848400_fcaf147-B15","doi-asserted-by":"crossref","first-page":"973226","DOI":"10.3389\/fneur.2022.973226","article-title":"Cranial autonomic symptoms and response to monoclonal antibodies targeting the calcitonin gene-related peptide pathway: A real-world study","volume":"13","author":"De Matteis","year":"2022","journal-title":"Front Neurol"},{"issue":"1","key":"2025042302470848400_fcaf147-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","article-title":"Association between response to triptans and response to erenumab: Real-life data","volume":"22","author":"Frattale","year":"2021","journal-title":"J Headache Pain"},{"key":"2025042302470848400_fcaf147-B17","doi-asserted-by":"crossref","first-page":"895476","DOI":"10.3389\/fneur.2022.895476","article-title":"Cerebral blood flow and other predictors of responsiveness to erenumab and fremanezumab in migraine\u2014A real-life study","volume":"13","author":"Nowaczewska","year":"2022","journal-title":"Front Neurol"},{"issue":"7","key":"2025042302470848400_fcaf147-B18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3390\/ph16070934","article-title":"A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: Predicting response","volume":"16","author":"Hong","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"2","key":"2025042302470848400_fcaf147-B19","doi-asserted-by":"crossref","first-page":"3331024221146315","DOI":"10.1177\/03331024221146315","article-title":"New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy","volume":"43","author":"Lee","year":"2023","journal-title":"Cephalalgia"},{"issue":"4","key":"2025042302470848400_fcaf147-B20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2025042302470848400_fcaf147-B21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s10194-023-01604-2","article-title":"The registry for migraine (REFORM) study: Methodology, demographics, and baseline clinical characteristics","volume":"24","author":"Karlsson","year":"2023","journal-title":"J Headache Pain"},{"issue":"1","key":"2025042302470848400_fcaf147-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache classification committee of the international headache society (IHS). the international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"2","key":"2025042302470848400_fcaf147-B23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ana.21211","article-title":"Cutaneous allodynia in the migraine population","volume":"63","author":"Lipton","year":"2008","journal-title":"Ann Neurol."},{"key":"2025042302470848400_fcaf147-B24","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1026119331193","article-title":"A six-item short-form survey for measuring headache impact: The HIT-6(TM)","volume":"12","author":"Kosinski","year":"2003","journal-title":"Qual Life Res."},{"key":"2025042302470848400_fcaf147-B25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7525-1-29","article-title":"The hospital anxiety and depression scale","volume":"1","author":"Snaith","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2025042302470848400_fcaf147-B26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0304-3959(00)00305-5","article-title":"Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers","volume":"88","author":"Stewart","year":"2000","journal-title":"Pain"},{"issue":"23","key":"2025042302470848400_fcaf147-B27","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1080\/09638288.2016.1223177","article-title":"World health organization disability assessment schedule 2.0: An international systematic review","volume":"39","author":"Federici","year":"2017","journal-title":"Disabil Rehabil"},{"issue":"5","key":"2025042302470848400_fcaf147-B28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults","volume":"38","author":"Tassorelli","year":"2018","journal-title":"Cephalalgia"},{"issue":"7","key":"2025042302470848400_fcaf147-B29","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American headache society consensus statement: Update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani","year":"2021","journal-title":"Headache"},{"issue":"3","key":"2025042302470848400_fcaf147-B30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0333102410379890","article-title":"Validation of the headache impact test (HIT-6TM) across episodic and chronic migraine","volume":"31","author":"Yang","year":"2011","journal-title":"Cephalalgia"},{"issue":"1","key":"2025042302470848400_fcaf147-B31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","article-title":"When and how should multiple imputation be used for handling missing data in randomised clinical trials\u2014A practical guide with flowcharts","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2025042302470848400_fcaf147-B32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Royal Statistical Society Series B (Methodological)"},{"key":"2025042302470848400_fcaf147-B33","author":"R Core Team"},{"issue":"14","key":"2025042302470848400_fcaf147-B34","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jama.2017.12126","article-title":"Discrimination and calibration of clinical prediction models: Users\u2019 guides to the medical literature","volume":"318","author":"Alba","year":"2017","journal-title":"JAMA"},{"key":"2025042302470848400_fcaf147-B35","doi-asserted-by":"crossref","first-page":"805334","DOI":"10.3389\/fneur.2021.805334","article-title":"Erenumab for migraine prevention in a 1-year compassionate use program: Efficacy, tolerability, and differences between clinical phenotypes","volume":"12","author":"Schoenen","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"2025042302470848400_fcaf147-B36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s10194-022-01456-2","article-title":"Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: A clinical service evaluation","volume":"23","author":"Lowe","year":"2022","journal-title":"J Headache Pain"},{"key":"2025042302470848400_fcaf147-B37","first-page":"251581632211281","article-title":"Predictors of clinical response to erenumab in patients with migraine","volume":"5","author":"Lekontseva","year":"2022","journal-title":"Cephalalgia Rep."},{"issue":"8","key":"2025042302470848400_fcaf147-B38","doi-asserted-by":"crossref","first-page":"e2260","DOI":"10.1002\/brb3.2260","article-title":"Predictors of response to erenumab after 12 months of treatment","volume":"11","author":"Baraldi","year":"2021","journal-title":"Brain Behav"},{"issue":"5","key":"2025042302470848400_fcaf147-B39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2024.0368","article-title":"Early use of erenumab vs nonspecific oral migraine preventives: The APPRAISE randomized clinical trial","volume":"81","author":"Pozo-Rosich","year":"2024","journal-title":"JAMA Neurol"},{"key":"2025042302470848400_fcaf147-B40","doi-asserted-by":"crossref","first-page":"104943","DOI":"10.1016\/j.ebiom.2023.104943","article-title":"Resistant and refractory migraine: Clinical presentation, pathophysiology, and management","volume":"99","author":"Ornello","year":"2024","journal-title":"eBioMedicine"},{"issue":"2","key":"2025042302470848400_fcaf147-B41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41588-021-00990-0","article-title":"Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles","volume":"54","author":"Hautakangas","year":"2022","journal-title":"Nat Genet"},{"issue":"1","key":"2025042302470848400_fcaf147-B42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-024-01790-7","article-title":"Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies\u2014Insights from the German NeuroTransData registry","volume":"25","author":"Hong","year":"2024","journal-title":"J Headache Pain"},{"issue":"5","key":"2025042302470848400_fcaf147-B43","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/ene.15260","article-title":"Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine","volume":"29","author":"Iannone","year":"2022","journal-title":"Eur J Neurol"},{"issue":"3","key":"2025042302470848400_fcaf147-B44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ane.13472","article-title":"Refractory migraine profile in CGRP-monoclonal antibodies scenario","volume":"144","author":"Silvestro","year":"2021","journal-title":"Acta Neurol Scand."},{"issue":"3","key":"2025042302470848400_fcaf147-B45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/pm\/pnad141","article-title":"Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: A multicenter real-world case-control study","volume":"25","author":"Gonzalez-Martinez","year":"2024","journal-title":"Pain Medicine"},{"issue":"10","key":"2025042302470848400_fcaf147-B46","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1474-4422(23)00206-5","article-title":"Migraine in older adults","volume":"22","author":"Hugger","year":"2023","journal-title":"Lancet Neurol"},{"issue":"2","key":"2025042302470848400_fcaf147-B47","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1526-4610.2006.00343.x","article-title":"Migraine in the elderly: A comparison with migraine in young adults","volume":"46","author":"Martins","year":"2006","journal-title":"Headache"},{"issue":"13","key":"2025042302470848400_fcaf147-B48","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.3390\/jcm10132898","article-title":"Onabotulinumtoxina in migraine: A review of the literature and factors associated with efficacy","volume":"10","author":"Ray","year":"2021","journal-title":"JCM"},{"issue":"11","key":"2025042302470848400_fcaf147-B49","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","article-title":"Late response to anti-CGRP monoclonal antibodies in migraine: A multicenter prospective observational study","volume":"101","author":"Barbanti","year":"2023","journal-title":"Neurology"},{"issue":"8","key":"2025042302470848400_fcaf147-B50","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"2025042302470848400_fcaf147-B51","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/head.13184","article-title":"Electronic-diary for recording headaches, triggers, and medication use: Development and evaluation","volume":"57","author":"Bandarian-Balooch","year":"2017","journal-title":"Headache"},{"issue":"10283","key":"2025042302470848400_fcaf147-B52","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","article-title":"Migraine: Disease characterisation, biomarkers, and precision medicine","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"2025042302470848400_fcaf147-B53","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41591-022-01981-2","article-title":"Multimodal biomedical AI","volume":"28","author":"Acosta","year":"2022","journal-title":"Nat Med"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaf147\/62928570\/fcaf147.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/2\/fcaf147\/62928570\/fcaf147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/2\/fcaf147\/62928570\/fcaf147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:47:22Z","timestamp":1745390842000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaf147\/8113425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaf147","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"fcaf147"}}